- Latest available (Revised)
- Point in Time (01/10/2003)
- Original (As made)
Version Superseded: 14/08/2012
Point in time view as at 01/10/2003.
There are currently no known outstanding effects for the The Medicines for Human Use (Marketing Authorisations Etc.) Amendment Regulations 2003 (revoked).
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
Statutory Instruments
MEDICINES
Made
20th June 2003
Laid before Parliament
27th June 2003
Coming into force
1st October 2003
The Secretary of State, being a Minister designated for the purposes of section 2(2) of the European Communities Act 1972 M1 in relation to medicinal products M2, in exercise of the powers conferred by the said section 2(2), and of all other powers enabling him in that behalf, hereby makes the following Regulations:—
1.—(1) These Regulations may be cited as the Medicines for Human Use (Marketing Authorisations Etc.) Amendment Regulations 2003 and shall come into force on 1st October 2003.
(2) In these Regulations, “the principal Regulations” means the Medicines for Human Use (Marketing Authorisations Etc.) Regulations 1994 M3.
Marginal Citations
M3S.I. 1994/3144; the relevant amending instruments are S.I. 1998/3105 and 2000/292.
2. After paragraph 5(1)(g) of Schedule 5 to the principal Regulations (labels — relevant medicinal products on a general sale list), there shall be added the following head—
“(h)if the product contains aspirin or aloxiprin, the words “Do not give to children aged under 16 years, unless on the advice of a doctor.”.”
3. After paragraph 2 of Schedule 5A to the principal Regulations (leaflets), there shall be added the following paragraph—
“3. Where in accordance with the relevant Community provisions a package leaflet is included in the packaging of a relevant medicinal product containing aspirin or aloxiprin, the leaflet shall display the words “There is a possible association between aspirin and Reye’s syndrome when given to children. Reye’s syndrome is a very rare disease, which can be fatal. For this reason aspirin should not be given to children aged under 16 years, unless on the advice of a doctor.”.”
Signed by authority of the Secretary of State for Health
Warner
Parliamentary Under Secretary of State
Department of Health
20th June 2003
(This note is not part of the Regulations)
These Regulations amend the Medicines for Human Use (Marketing Authorisations Etc.) Regulations 1994 (“the principal Regulations”) which implement Council Directive 2001/83/EEC (O.J. No. L311 of 28.11.2001) by requiring necessary special warnings to be included on the packaging of relevant medicinal products containing aspirin or aloxiprin, and in package leaflets accompanying those products.
A Regulatory Impact Assessment in relation to these Regulations has been placed in the libraries of both Houses of Parliament, and copies can be obtained from the Medicines and Healthcare Products Regulatory Agency, Market Towers, 1 Nine Elms Lane, London SW8 5NQ.
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: